PRESS RELEASE: IVI’s Updated RA Model Examines New Treatment Options, Treatment Effects and Cost Estimates
IVI has just released the latest update to the organization's Rheumatoid Arthritis (RA) Value Assessment Model. The updated model now incorporates additional treatment options (triple therapy, Janus Kinase (JAK) inhibitors, sarilumab, and biosimilars), updated treatment [...]
PRESS RELEASE: IVI Research Brief Discusses Limitations of ICER’s Analysis for JAK Inhibitors
As part of its Value Blueprints series, IVI’s latest research brief grapples with a question prompted by ICER’s recent assessment of RA therapies: Do conventional value assessments address the questions most relevant to real-world decisions [...]
IVI Showcases OSVP at HealthEconomics.com’s “Big Ideas Accelerating Change” Challenge
As one of the nine finalists in HealthEconomics.com's inaugural challenge competition to accelerate change in health economics and outcomes research, IVI's Mark Linthicum offered a compelling case for how IVI's Open-Source Value Platform (OSVP) is [...]
IVI Submits Comments on ICER Draft Evidence Report on JAK Inhibitors for RA
IVI offered comments on ICER's recently released Draft Evidence Report examining the cost-effectiveness of Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis. In addition to commenting on the needs for transparency and the impacts of modeling [...]
Jennifer Bright Explains How IVI Economic Models Improve Process of Value Assessment
At the National Health Council's event, Back to School: Patient Community Training on Value Assessment, IVI executive director Jennifer Bright explains the non-profit organization's mission to make value assessment more relevant to real decision making, [...]
IVI Presents Two Posters at AMCP Nexus 2019
IVI presented two posters at AMCP Nexus 2019, the healthcare conference at the intersection of value and care. In the poster “Understanding Value Through the Patient’s Eyes: Perspectives from Patients with Genetic Mutations in Non-Small [...]
Top Three Questions Employers Need to Ask Benefits Consultants
Jennifer Bright writes in Benefits Pro that employers who rely on health plans and vendors to advise them on coverage for drugs or other treatments need to ask several key questions to ensure they are [...]
PRESS RELEASE: IVI Receives Eugene Washington PCORI Engagement Award
IVI has been selected by the Patient-Centered Outcomes Research Institute (PCORI) for a Eugene Washington PCORI Engagement Award. The $50,000 award will be used to convene a multi-stakeholder forum in February 2020 to review established [...]
IVI Comment Letter on ICER’s Proposed Methods for Curative Therapies
IVI submitted comments to ICER regarding proposed methodological changes for assessments of the value of single or short-term transformative (SST) therapies. IVI emphasized the need for ICER to address the potential use of its findings [...]
PRESS RELEASE: How Structural Uncertainty Impacts Value Estimates
In a new Value Blueprints research brief, IVI explores the concept of “structural uncertainty,” an important source of uncertainty that is not generally measured or addressed in cost-effectiveness models. In this research brief, we use [...]
2-Minute Drill: Jeroen Jansen on How to Improve Value Assessment
At the 2019 ISPOR conference, Jeroen Jansen sat down with AJMC to explain the current state of value assessment and how by putting patients at the frontend of analysis, we can better quantify the value [...]
Watch Devin Incerti Discuss the Need for Adaptable Value Assessment Approaches
Devin Incerti sat down with the AJMC media team at the 2019 ISPOR conference to discuss how value is context-specific and therefore value assessment should be too. Watch the interview here.